Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB1102 in Advanced Solid Tumors
NCT02561234Phase 1Completed
- Sponsor
- Immedica
- Start
- Oct 2015
- Primary completion
- May 2019
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegzilarginase in solid tumor, cutaneous melanoma (CM), Uveal Melanoma (UM) and 1 more (12 arms), sponsored by Immedica. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Oct 2015; status: completed.
02
Drugs
pegzilarginase
03
Conditions
solid tumorcutaneous melanoma (CM)Uveal Melanoma (UM)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02561234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561234.